SCHEMBL4415716

SCHEMBL4415716

CCOC(=O)c1ccc(S(C)(=O)=O)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 7/20 0.48
GABRG2 P18507 7/20 0.48
GABRB3 P28472 7/20 0.48
GABRA5 P31644 7/20 0.48
GABRA3 P34903 7/20 0.48
GABRA2 P47869 7/20 0.48
GABRA4 P48169 7/20 0.48
GABRA6 Q16445 7/20 0.48
GABRP O00591 6/20 0.48
GABRD O14764 6/20 0.48
GABRB1 P18505 6/20 0.48
GABRB2 P47870 6/20 0.48
GABRE P78334 6/20 0.48
GABRG1 Q8N1C3 6/20 0.48
GABRG3 Q99928 6/20 0.48
GABRQ Q9UN88 6/20 0.48
CYP1A2 P05177 1/20 0.47
PTGS2 P35354 2/20 0.47
ALDH1A1 P00352 4/20 0.46
NPC1 O15118 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19212530 0.84 ALDH1A1 (0.52) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL30555263 0.82 MAPK1 (0.59) PTGS2ALDH1A1NPC1MAPK1KDM4E
SCHEMBL9901479 0.82 MAPK1 (0.59) PTGS2ALDH1A1NPC1MAPK1KDM4E
SCHEMBL31172628 0.78 CYP1A2 (0.55) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL82426 0.78 CYP1A2 (0.55) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL29637478 0.77 MAPK1 (0.61) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL229176 0.77 CA12 (0.55) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL1971939 0.77 MAPK1 (0.61) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL10003611 0.77 CYP1A2 (0.53) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL4326059 0.76 PTGS2 (0.55) CYP1A2PTGS2ALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
EP-1907383-A1 GPCR AGONISTS Prosidion Limited (GB) 2008-04-09 EP disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 GABRA1 217/4885GABRG2 212/4885GABRB3 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.